MN HF2009

Prohibits health plans and the Minnesota Department of Human Services from requiring step therapy protocols for FDA-approved drugs used to treat stage four advanced metastatic cancer if the drug is consistent with FDA-approved indications and National Comprehensive Cancer Network clinical practice guidelines.

Applies to all health plans including county-based purchasing plans and integrated health partnerships participating in public programs under Minnesota Statutes chapters 256B and 256L.

Defines "stage four advanced metastatic cancer" as cancer that has spread from the primary site to nearby tissues, lymph nodes, or other parts of the body.

Requires any step therapy protocol requirements established by the commissioner for Medicaid drugs to comply with the new prohibition on step therapy for metastatic cancer treatment.

Effective January 1, 2020, and applies to health plans offered, issued, or renewed on or after that date.